AVNS
Avanos Medical, Inc. NYSE Listed Oct 21, 2014$24.94
+0.28%
vs $24.87
Mkt Cap $1.2B
52w Low $9.89
99.3% of range
52w High $25.05
50d MA $24.15
200d MA $15.37
P/E (TTM)
-17.1x
EV/EBITDA
—
P/B
1.5x
Debt/Equity
0.2x
ROE
-9.4%
P/FCF
26.8x
RSI (14)
60.00
ATR (14)
$0.11
Beta
1.05
50d MA
$24.15
200d MA
$15.37
Avg Volume
1.3M
Avanos Medical, Inc., a medical technology company, focuses on delivering medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions; and respiratory health products, such as closed airway suction systems and other airway management devices under the Ballard, Microcuff, and Endoclear brands. The company also provides a portfolio of non-opioid pain solutions, including acute pain products, such as On-Q and ambIT surgical pain pumps, Game Ready cold, and compression therapy systems; and interventional pain solutions, which offers minimally invasive pain-relieving therapies, such as Coolief pain relief therapy. It markets its products directly to hospitals and other healthcare providers, healthcare facilities, and other end-user customers, as well as through third-party wholesale distributors. The company was formerly known as Halyard Health, Inc. and changed its name to Avanos Medical, Inc. in June 2018. Avanos Medical, Inc. was incorporated in 2014 and is headquartered in Alpharetta, Georgia.
5405 Windward Parkway · Alpharetta, GA 30004 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 24, 2026 | AMC | 0.24 | 0.29 | +20.8% | 13.64 | +0.1% | +5.3% | +0.9% | -2.7% | -0.9% | +0.1% | — |
| Nov 5, 2025 | AMC | 0.12 | 0.22 | +83.3% | 10.66 | +0.7% | +4.9% | +0.4% | +1.9% | +1.9% | +0.9% | — |
| Aug 5, 2025 | AMC | 0.18 | 0.17 | -5.6% | 9.89 | +0.1% | +4.4% | +4.0% | +0.7% | -2.8% | +2.6% | — |
| May 6, 2025 | AMC | 0.19 | 0.26 | +36.8% | 12.85 | -0.1% | -2.1% | +0.0% | +0.6% | +3.6% | -3.0% | — |
| Feb 26, 2025 | AMC | 0.40 | 0.43 | +7.5% | 15.62 | -1.7% | -2.6% | -1.1% | +0.5% | -0.7% | +1.9% | — |
| Oct 30, 2024 | AMC | 0.36 | 0.36 | +0.0% | 18.58 | +1.0% | +0.5% | +0.2% | +2.7% | +3.0% | +5.9% | — |
| Jul 31, 2024 | AMC | 0.29 | 0.34 | +17.2% | 23.92 | -0.2% | -0.7% | +1.1% | -4.4% | -0.0% | -2.0% | — |
| May 2, 2024 | AMC | 0.21 | 0.22 | +4.8% | 19.71 | +1.2% | -0.2% | +0.3% | -1.0% | +0.1% | -0.5% | — |
| Feb 20, 2024 | AMC | 0.37 | 0.36 | -2.7% | 19.50 | +0.4% | +0.1% | +0.4% | +0.5% | -2.1% | +0.4% | — |
| Nov 1, 2023 | AMC | 0.29 | 0.30 | +3.4% | 20.79 | -0.6% | +3.5% | +2.6% | -1.7% | -2.4% | -0.5% | — |
| Aug 9, 2023 | AMC | 0.34 | 0.24 | -29.4% | 23.41 | -0.2% | -0.6% | -3.0% | -0.8% | -0.6% | -1.3% | — |
| May 3, 2023 | AMC | 0.28 | 0.27 | -3.6% | 24.44 | -3.7% | -3.7% | +1.8% | -2.2% | -1.8% | +1.3% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jul 25 | KeyBanc Capital Markets | Downgrade | Overweight → Sector Weight | — | $25.54 | $24.29 | -4.9% | -4.3% | +1.3% | -1.8% | +0.2% | +0.3% |
| Jun 21 | Stifel | Maintains | Hold → Hold | — | $25.59 | $25.50 | -0.4% | +0.1% | +1.9% | -0.8% | -1.4% | +0.2% |
| May 4 | Morgan Stanley | Maintains | Underweight → Underweight | — | $24.44 | $23.53 | -3.7% | -3.7% | +1.8% | -2.2% | -1.8% | +1.3% |
| Feb 22 | Morgan Stanley | Maintains | Underweight → Underweight | — | $29.01 | $29.03 | +0.1% | +0.4% | +0.6% | -2.2% | -1.4% | -0.7% |
| Jan 6 | Morgan Stanley | Maintains | Underweight → Underweight | — | $26.92 | $27.23 | +1.2% | +0.5% | -0.3% | +1.7% | +1.6% | +3.7% |
| Nov 3 | KeyBanc Capital Markets | Maintains | Overweight → Overweight | — | $23.17 | $22.73 | -1.9% | -3.3% | +1.5% | +5.7% | -0.5% | +1.2% |
| Oct 11 | Morgan Stanley | Maintains | Underweight → Underweight | — | $20.94 | $20.62 | -1.5% | -1.1% | -4.0% | +2.0% | -1.4% | +5.3% |
| Aug 10 | KeyBanc Capital Markets | Maintains | Overweight → Overweight | — | $28.84 | $28.80 | -0.1% | -2.2% | +0.4% | +2.8% | +1.7% | -4.1% |
| Jul 18 | Stifel | Maintains | Hold → Hold | — | $26.85 | $26.84 | -0.0% | -1.5% | +3.6% | +0.2% | +1.8% | -0.6% |
| Jul 15 | Morgan Stanley | Maintains | Underweight → Underweight | — | $26.30 | $26.84 | +2.1% | +2.1% | -1.5% | +3.6% | +0.2% | +1.8% |
| May 5 | Morgan Stanley | Maintains | Underweight → Underweight | — | $30.73 | $29.84 | -2.9% | -4.2% | -5.8% | -7.4% | -1.3% | -1.1% |
| Feb 24 | KeyBanc Capital Markets | Maintains | Overweight → Overweight | — | $31.69 | $31.48 | -0.7% | +7.2% | +4.2% | -0.0% | -1.3% | -0.9% |
| Jan 7 | Morgan Stanley | Maintains | Underweight → Underweight | — | $34.52 | $33.73 | -2.3% | -3.5% | +2.6% | -4.4% | -1.6% | +1.4% |
| Aug 4 | KeyBanc Capital Markets | Maintains | Overweight → Overweight | — | $36.93 | $35.05 | -5.1% | -8.0% | +0.2% | +2.0% | -2.2% | -1.3% |
| Aug 4 | Stephens & Co. | Downgrade | Overweight → Equal Weight | — | $36.93 | $35.05 | -5.1% | -8.0% | +0.2% | +2.0% | -2.2% | -1.3% |
| Aug 4 | Morgan Stanley | Maintains | Underweight → Underweight | — | $36.93 | $35.05 | -5.1% | -8.0% | +0.2% | +2.0% | -2.2% | -1.3% |
| Jan 8 | KeyBanc | Maintains | Overweight → Overweight | — | $48.58 | $49.22 | +1.3% | -1.1% | -0.2% | +0.5% | -0.2% | +0.7% |
| Dec 15 | Morgan Stanley | Maintains | Underweight → Underweight | — | $47.27 | $48.07 | +1.7% | +1.2% | +0.5% | +3.0% | -3.0% | -3.0% |
| Nov 4 | KeyBanc | Maintains | Overweight → Overweight | — | $40.32 | $40.13 | -0.5% | +0.5% | -1.6% | -0.3% | +4.4% | +2.8% |
| Nov 4 | KeyBanc Capital Markets | Maintains | Overweight → Overweight | — | $40.32 | $40.13 | -0.5% | +0.5% | -1.6% | -0.3% | +4.4% | +2.8% |
| Nov 4 | Morgan Stanley | Maintains | Underweight → Underweight | — | $40.32 | $40.13 | -0.5% | +0.5% | -1.6% | -0.3% | +4.4% | +2.8% |
| Aug 5 | KeyBanc Capital Markets | Maintains | Overweight → Overweight | — | $32.50 | $32.62 | +0.4% | -4.9% | -0.1% | +0.9% | +0.1% | +1.8% |
| Aug 5 | KeyBanc | Maintains | Overweight → Overweight | — | $32.50 | $32.62 | +0.4% | -4.9% | -0.1% | +0.9% | +0.1% | +1.8% |
| May 7 | Morgan Stanley | Maintains | Underweight → Underweight | — | $30.36 | $31.15 | +2.6% | -4.9% | -2.7% | +0.5% | -4.6% | -4.3% |
| Apr 27 | KeyBanc Capital Markets | Maintains | Overweight → Overweight | — | $29.99 | $30.32 | +1.1% | +4.9% | -2.7% | +4.9% | -3.3% | +0.1% |
| Apr 27 | KeyBanc | Maintains | Overweight → Overweight | — | $29.99 | $30.32 | +1.1% | +4.9% | -2.7% | +4.9% | -3.3% | +0.1% |
| Apr 13 | Barclays | Upgrade | Underweight → Equal Weight | — | $28.95 | $29.06 | +0.4% | -2.0% | +9.1% | -7.2% | +2.6% | +4.7% |
| Apr 1 | Stifel | Maintains | Hold → Hold | — | $26.93 | $25.49 | -5.3% | -12.8% | +4.9% | -3.5% | +8.3% | +0.8% |
| Mar 27 | Morgan Stanley | Maintains | Underweight → Underweight | — | $25.58 | $24.49 | -4.3% | -2.0% | +7.8% | -0.3% | -12.8% | +4.9% |
| Mar 23 | Stephens & Co. | Maintains | Overweight → Overweight | — | $21.14 | $21.39 | +1.2% | -2.4% | +12.5% | -1.2% | +11.5% | -2.0% |
| Dec 17 | Morgan Stanley | Maintains | Underweight → Underweight | — | $33.24 | $32.84 | -1.2% | -3.6% | +1.9% | +0.4% | -0.5% | +3.3% |
| Nov 7 | Stifel | Downgrade | Buy → Hold | — | $34.27 | $34.00 | -0.8% | -1.0% | +4.7% | -3.5% | -1.5% | -3.5% |
| Nov 6 | KeyBanc Capital Markets | Maintains | Overweight → Overweight | — | $37.08 | $35.85 | -3.3% | -7.6% | -1.0% | +4.7% | -3.5% | -1.5% |
| Nov 6 | Raymond James | Downgrade | Outperform → Market Perform | — | $37.08 | $35.85 | -3.3% | -7.6% | -1.0% | +4.7% | -3.5% | -1.5% |
| Nov 6 | KeyBanc | Maintains | Overweight → Overweight | — | $37.08 | $35.85 | -3.3% | -7.6% | -1.0% | +4.7% | -3.5% | -1.5% |
| Aug 7 | Raymond James | Maintains | Outperform → Outperform | — | $37.23 | $37.00 | -0.6% | -1.7% | +5.8% | -1.4% | -2.0% | -1.1% |
| Feb 27 | KeyBanc | Maintains | Overweight → Overweight | — | $50.50 | $50.15 | -0.7% | -5.7% | -1.2% | +1.7% | +1.1% | -3.1% |
| Feb 27 | KeyBanc Capital Markets | Maintains | Overweight → Overweight | — | $50.50 | $50.15 | -0.7% | -5.7% | -1.2% | +1.7% | +1.1% | -3.1% |
| Jan 4 | Barclays | Downgrade | Equal Weight → Underweight | — | $41.49 | $38.15 | -8.1% | -4.0% | +5.5% | +2.4% | +3.7% | +0.6% |
| Dec 18 | KeyBanc Capital Markets | Maintains | Overweight → Overweight | — | $47.59 | $47.60 | +0.0% | -0.4% | -5.7% | -1.6% | -2.2% | -4.3% |
| Dec 18 | KeyBanc | Maintains | Overweight → Overweight | — | $47.59 | $47.60 | +0.0% | -0.4% | -5.7% | -1.6% | -2.2% | -4.3% |
| Oct 11 | Morgan Stanley | Maintains | Underweight → Underweight | — | $61.48 | $61.10 | -0.6% | -3.3% | -0.0% | +0.9% | +2.8% | +0.6% |
| Aug 21 | Raymond James | Upgrade | Market Perform → Outperform | — | $66.05 | $69.60 | +5.4% | +5.5% | +2.7% | +0.6% | +0.4% | -0.2% |
| Aug 8 | KeyBanc Capital Markets | Maintains | Overweight → Overweight | — | $65.75 | $65.50 | -0.4% | -3.0% | -1.0% | -0.6% | -0.3% | +1.1% |
| Aug 8 | Morgan Stanley | Maintains | Underweight → Underweight | — | $65.75 | $65.50 | -0.4% | -3.0% | -1.0% | -0.6% | -0.3% | +1.1% |
| Aug 8 | KeyBanc | Maintains | Overweight → Overweight | — | $65.75 | $65.50 | -0.4% | -3.0% | -1.0% | -0.6% | -0.3% | +1.1% |
No insider trades available.
8-K · 2.02
!! High
Avanos Medical, Inc. -- 8-K 2.02: Earnings Results
Avanos Medical reported Q1 2026 earnings on May 5, 2026, providing investors with updated financial performance metrics and operational results for the quarter.
May 5
8-K · 1.01
!!! Very High
Unknown — 8-K 1.01: Merger Agreement
AVNS shareholders will likely face significant dilution or a below-market acquisition price, as private equity takeovers typically involve substantial management fees and leverage that prioritize buyer returns over public shareholders.
Apr 14
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
The departure of a key executive at Avans could disrupt operational continuity and investor confidence, particularly if no qualified successor is immediately named, potentially pressuring the stock near-term.
Mar 12
8-K · 8.01
!! High
Avanos Medical, Inc. -- 8-K 8.01: Material Event / Announcement
Avanos Medical announced it will nominate Mr. Cunniff to its Board of Directors at the 2026 Annual Meeting, signaling potential strategic leadership changes.
Feb 26
8-K
Avanos Medical, Inc. -- 8-K Filing
This appears to be a routine investor relations contact update for Avanos Medical rather than a material corporate event requiring investor analysis.
Feb 24
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Vanguard Capital Management Llc | 1,971,965 | $28M | New | Mar 2026 |
| 2 | Morgan Stanley | 2,188,072 | $25M | Added | Dec 2025 |
| 3 | Vanguard Portfolio Management Llc | 1,239,295 | $17M | New | Mar 2026 |
| 4 | Acadian Asset Management Llc | 1,214,930 | $17M | Added | Mar 2026 |
| 5 | Clark Estates Inc/ny | 888,880 | $10M | Added | Dec 2025 |
| 6 | Aqr Capital Management Llc | 691,250 | $10M | Reduced | Mar 2026 |
| 7 | D.e. Shaw & Co | 671,413 | $9M | Reduced | Mar 2026 |
| 8 | Northern Trust Corp | 489,221 | $7M | Added | Mar 2026 |
| 9 | Citadel Advisors Llc | 475,196 | $7M | Reduced | Mar 2026 |
| 10 | Diamond Hill Capital Management Inc | 509,702 | $6M | Added | Dec 2025 |
| 11 | Fmr Llc | 380,561 | $5M | Added | Mar 2026 |
| 12 | Bank Of New York Mellon Corp | 304,726 | $4M | — | Mar 2026 |
| 13 | Jpmorgan Chase & Co | 251,162 | $3M | Reduced | Mar 2026 |
| 14 | Principal Financial Group Inc | 292,832 | $3M | Added | Dec 2025 |
| 15 | Invesco Ltd. | 211,054 | $3M | Reduced | Mar 2026 |
| 16 | Franklin Resources Inc | 188,953 | $3M | Added | Mar 2026 |
| 17 | Martingale Asset Management L P | 180,360 | $3M | Added | Mar 2026 |
| 18 | Vestgen Advisors, Llc | 101,063 | $2M | New | Mar 2026 |
| 19 | Sei Investments Co | 167,936 | $2M | Added | Mar 2026 |
| 20 | Quantinno Capital Management Lp | 149,866 | $2M | — | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$1.16B
Enterprise Value
$1.16B
P/E (TTM)
-17.08x
Forward P/E
24.94x
PEG Ratio
0.09x
P/B
1.49x
P/S
1.65x
P/FCF
26.85x
EV/EBITDA
—
Shares Out
46.4M
Financials (TTM)
Revenue
$701.2M
Net Income
-$67.9M
EBITDA
-$33.2M
Free Cash Flow
$43.1M
Op Cash Flow
$74.7M
EPS Basic
$-1.46
EPS Diluted
$-1.46
EPS Forward
$1.00
Gross Margin
49.8%
Op Margin
-8.8%
Net Margin
-9.7%
Balance Sheet
Total Assets
$1.07B
Total Liab.
$295.5M
Total Equity
$778.2M
Cash
$89.8M
LT Debt
$90.3M
Book Value/Sh
$16.77
Debt/Equity
0.17x
Current Ratio
2.15
Quick Ratio
1.26
Returns & Growth
ROE
-9.4%
ROA
-6.8%
ROIC
-6.7%
Rev Growth YoY
+1.9%
EPS Growth YoY
+82.9%
Price Returns
2W
+0.4%
1M
+0.8%
3M
+75.9%
6M
+111.3%
12M
+97.3%
Technicals
52W High
$25.05
52W Low
$9.89
50d MA
$24.15
200d MA
$15.37
RSI (14)
60.00
ATR (14)
$0.11
Beta
1.05
Avg Volume
1.3M
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$23.00
High
$26.00
Low
$20.00
Median
$23.00
Data updated apr 24, 2026 7:59pm
· Source: financialmodelingprep.com